XML 26 R4.htm IDEA: XBRL DOCUMENT v3.6.0.2
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Revenue:      
Net revenue - collaboration $ 171,965    
Net revenue - commercial product sales 1,895    
Revenue - bulk insulin sales 898    
Total net revenue 174,758    
Expenses:      
Costs of revenue - collaboration 32,971    
Cost of goods sold 17,121 $ 64,745  
Research and development 14,917 29,674 $ 100,244
Selling, general and administrative 46,928 40,960 79,383
Property and equipment impairment 1,259 140,412 0
(Gain) loss on foreign currency translation (3,433) 2,697  
(Gain) loss on purchase commitments (2,265) 66,167  
Total expenses 107,498 344,655 179,627
Income (loss) from operations 67,260 (344,655) (179,627)
Other income (expense):      
Change in fair value of warrant liability 5,369    
Interest income 85 18 9
Interest expense on notes (15,576) (21,231) (17,549)
Interest expense on note payable to principal stockholder (2,901) (2,894) (2,894)
Gain (loss) on extinguishment of debt 72,024 (1,049)  
Other (expense) income (597) 1,366 1,679
Total other income (expense) 58,404 (23,790) (18,755)
Income (loss) before benefit for income taxes 125,664 (368,445) (198,382)
Income tax benefit 0 0 0
Net income (loss) $ 125,664 $ (368,445) $ (198,382)
Net income (loss) per share - basic $ 1.37 $ (4.54) $ (2.57)
Net income (loss) per share - diluted $ 1.36 $ (4.54) $ (2.57)
Shares used to compute basic net income (loss) per share 92,053 81,233 77,045
Shares used to compute diluted net income (loss) per share 92,085 81,233 77,045